These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11940217)

  • 1. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.
    Tsuda H; Sasano H; Akiyama F; Kurosumi M; Hasegawa T; Osamura RY; Sakamoto G
    Pathol Int; 2002 Feb; 52(2):126-34. PubMed ID: 11940217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
    Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
    Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.
    Hoang MP; Sahin AA; Ordòñez NG; Sneige N
    Am J Clin Pathol; 2000 Jun; 113(6):852-9. PubMed ID: 10874886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
    Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
    Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
    J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma.
    Tsuda H; Tani Y; Hasegawa T; Fukutomi T
    Pathol Int; 2001 Jan; 51(1):26-32. PubMed ID: 11148460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry.
    O'Malley FP; Parkes R; Latta E; Tjan S; Zadro T; Mueller R; Arneson N; Blackstein M; Andrulis I
    Am J Clin Pathol; 2001 Apr; 115(4):504-11. PubMed ID: 11293897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility.
    Santinelli A; Baccarini M; Colanzi P; Stramazzotti D; Fabris G
    Anal Quant Cytol Histol; 2002 Feb; 24(1):54-62. PubMed ID: 11865950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
    Tsuda H; Akiyama F; Terasaki H; Hasegawa T; Kurosumi M; Shimadzu M; Yamamori S; Sakamoto G
    Cancer; 2001 Dec; 92(12):2965-74. PubMed ID: 11753973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH).
    Mayr D; Heim S; Werhan C; Zeindl-Eberhart E; Kirchner T
    Virchows Arch; 2009 Mar; 454(3):241-8. PubMed ID: 19169706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.
    Hsu CY; Ho DM; Yang CF; Lai CR; Yu IT; Chiang H
    Am J Clin Pathol; 2002 Nov; 118(5):693-8. PubMed ID: 12428788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating HER2 amplification and overexpression in breast cancer.
    Bartlett JM; Going JJ; Mallon EA; Watters AD; Reeves JR; Stanton P; Richmond J; Donald B; Ferrier R; Cooke TG
    J Pathol; 2001 Nov; 195(4):422-8. PubMed ID: 11745673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.